NINE ALLIPAR : New Financial Obligation - Form 8-K
March 04, 2024 at 03:26 pm EST
Share
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
Coretag Holdings, Inc, (the "Company"), as the "Borrower" and Mr. Joseph Passalaqua ("Passalaqua") as the "Lender" have previously entered into various Promissory Notes whereby Passalaqua made hard money loans to the Company, the Company and Passalaqua have entered into the following Promissory Notes covering those periods and in the amounts as set forth therein. The following Promissory Notes cover all of the amounts due and owing by the Company to Passalaqua as previously reported in the Company's Quarterly and Annual Reports, as the case may be. Additionally, the following Promissory Notes are non-convertible and become due and payable, on the terms and conditions as fully set forth therein:
(i) On October 16, 2023, the Company and Passalaqua entered into a Promissory Note relating to various loans made by Passalaqua to the Company over the period from October 1, 2021, through September 30, 2022 in the aggregate amount of $14,424.00, which shall become due and payable on the 18th month anniversary thereof, a copy of which is attached here to as Exhibit 10.1; (ii) On October 16, 2023, the Company and Passalaqua entered into a Promissory Note relating to various loans made by Passalaqua to the Company over the period from October 1, 2022, through June 30, 2023 in the aggregate amount of $26,173.00, which shall become due and payable on the 18th month anniversary thereof, a copy of which is attached here to as Exhibit 10.2; (iii) On March 1, 2024, the Company and Passalaqua entered into a Promissory Note relating to various loans made by Passalaqua to the Company over the period from July 1, 2023, through September 30, 2023 in the aggregate amount of $5,820.00, which shall become due and payable on the 18th month anniversary thereof, a copy of which is attached here to as Exhibit 10.3; (iv) On March 1, 2024, the Company and Passalaqua entered into a Promissory Note relating to various loans made by Passalaqua to the Company over the period from October 1, 2023, through December 31, 2023 in the aggregate amount of $10,731.00, which shall become due and payable on the 18th month anniversary thereof, a copy of which is attached here to as Exhibit 10.4.
The entry into the foregoing Promissory Notes, by the Company and Passalaqua, reflects the understandings by and between the parties that they deem to be a fair and equitable resolution to the debt due and owing Passalaqua.
Attachments
Original Link
Permalink
Disclaimer
Nine Alliance Science & Technology Group published this content on
04 March 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
04 March 2024 20:26:06 UTC.
Coretag, Inc. is focused on the development of cancer imaging and targeted radiotherapy, based on its Necrosis Targeting Platform Technology (NTPT). The Company developed NTPT as a result of the discovery of a group of cyanine dyes which have selective targeting properties for intracellular proteins. These proteins become available for binding only when the cell membrane loses its integrity, which occurs once a cell has become necrotic. The Company has developed a portfolio of products that address high unmet needs in oncology. The Company develops targeted radiotherapy with 177Lu (lutetium) and 121Pb (lead) for the treatment of rapidly growing tumors and metastasis. It also develops targeted diagnostics with 89Zr (zirconium) and 111In (indium) for detecting and quantifying necrotic tissue in the human body.